Skip to main content
. 2023 Feb 15;13(2):654–668.

Figure 2.

Figure 2

Kaplan-Meier analyses of progression-free survival. A. All patients. B. Patients with or without macrovascular invasion (MVI). C. Patients with or without combination therapy. D. Patients with or without disease control. E. Patients in different groups according to the combination of CRAFITY score and AFP response (CRAFITY/AFPr). Progression-free survival is presented as median (95% confidence interval). AFP, α-fetoprotein; CRAFITY, C-reactive protein and α-fetoprotein in immunotherapy; mPFS, median progression-free survival.